Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, BLS Pharmaceuticals's average Book Value per Share Growth Rate was 160.00% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 25.30% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 3.70% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -4.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of BLS Pharmaceuticals was 137.50% per year. The lowest was -71.60% per year. And the median was -21.00% per year.
BLS Pharmaceuticals (ASX:BLS) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
BLS Pharmaceuticals 3-Year Book Growth Rate Related Terms
ASX:BLS vs VRTX, REGN, RVMD: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, BLS Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's 3-Year Book Growth Rate falls into.
BLS Pharmaceuticals 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 25.30% mean?
BLS Pharmaceuticals (ASX:BLS) has a 3-Year Book Growth Rate of 25.30% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for BLS Pharmaceuticals and its competitors. According to the industry distribution chart, BLS Pharmaceuticals ranks #149 out of 1131 companies in the Biotechnology industry, placing it in the top 13.2%.
Is BLS Pharmaceuticals' 3-Year Book Growth Rate too high?
BLS Pharmaceuticals' current 3-Year Book Growth Rate is 25.30%. Based on the distribution chart, BLS Pharmaceuticals ranks #149 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #149 out of 1131 companies for 3-Year Book Growth Rate. This places BLS Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for BLS Pharmaceuticals and its competitors. BLS Pharmaceuticals's current 3-Year Book Growth Rate is 25.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.71, compared to a current price of A$0.92 — trading 29.6% above its estimated fair value. The current 3-Year Book Growth Rate is 25.30%. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current 3-Year Book Growth Rate is 25.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.92 is trading 29.6% above its estimated GF Value™ of A$0.71.
GuruFocus considers BLS Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ASX:BLS:
3-Year Book Growth Rate: 25.30%
GF Value™: A$0.71 vs. price of A$0.92 (29.6% above fair value)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
